Disease Markers

Disease Markers / 2009 / Article

Open Access

Volume 27 |Article ID 497519 | 7 pages | https://doi.org/10.3233/DMA-2009-0649

Homocysteine Disulphides and Vascular Disease

Received28 Oct 2009
Accepted28 Oct 2009


The total plasma concentration of homocysteine is a marker of this amino acid's atherogenic potential. However, the homocysteine pool exists almost entirely as oxidized homocysteine equivalents (OHcyE), composed of homocystine and cysteine-homocysteine disulphides (20–30%), and protein-bound disulphide (70–80%). We have noticed that the total concentration of OHcyE in injured coronary artery tissue is higher than the aqueous solubility of homocystine (∼1.4–1.5 × 10-3 mol kg-1 versus ∼0.6 mol kg-1). Based on the measurement of the solubility of homocystine in a plasma-mimetic condition (0.17 mol kg-1 NaCl at 37°C), we have estimated that OHcyE may really reach their saturation limit in the vascular tissue (0.93–1.02 × 10-3 mol kg-1), above which their deposition as solid phase may occur. This means that significant leakage of intracellular fluid can promote OHcyE crystallization in tissue fluids, which may serve to initiate inflammation. We speculate that deposition of OHcyE crystals could damage blood vessels and act as a primer of homocysteine-triggered inflammation, thus being along the causal pathway that leads to vascular dysfunction.

Copyright © 2009 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

384 Views | 384 Downloads | 1 Citation
 PDF  Download Citation  Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.